Daiichi Sankyo Europe, Gmbh, A Daiichi Sankyo Company

This study follows over 1,100 adults with HER2-low breast cancer that cannot be removed by surgery or has spread. Researchers will compare how long patients stay on trastuzumab deruxtecan (a targeted drug) versus standard chemotherapy before needing a new treatment. The goal is t…

This study looks at how well a combination of three cholesterol-lowering medicines (bempedoic acid, ezetimibe, and a statin) works in real-world patients with high cholesterol or mixed lipid problems. About 2,000 adults at high or very high risk will be followed for up to a year.…

This study follows about 257 adults with advanced HER2-positive stomach or gastroesophageal junction cancer who have already tried a trastuzumab-based treatment. Researchers will track how well the drug trastuzumab deruxtecan (T-DXd) works in everyday medical practice, including …